Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| ID | DOID:5744 |
| Name | ovary serous adenocarcinoma |
| Definition | An ovary adenocarcinoma that derives_from the lining of a cavity that produces a serum-like fluid (a serous cavity). |
| Source | DiseaseOntology.org |
| Alt Ids | DOID:5745 |
| Path | disease disease of cellular proliferation cancer organ system cancer reproductive organ cancer female reproductive organ cancer ovarian cancer ovary epithelial cancer malignant ovarian surface epithelial-stromal neoplasm ovarian carcinoma ovary adenocarcinoma ovary serous adenocarcinoma |
| Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
|---|---|---|---|---|
| RAD51B wild-type | Cediranib + Olaparib | ovary serous adenocarcinoma | predicted - sensitive | detail... |
| RAD51B mutant | Cediranib + Olaparib | ovary serous adenocarcinoma | predicted - sensitive | detail... |
| BRAF V600E | Vemurafenib | ovary serous adenocarcinoma | predicted - sensitive | detail... |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT01853306 | Phase I | Veliparib | A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid Tumors | Completed | 0 | |
| NCT02068794 | Phase Ib/II | MV-NIS | MV-NIS Infected Mesenchymal Stem Cells in Treating Patients With Recurrent Ovarian Cancer | Active, not recruiting | USA | 0 |
| NCT02282020 | Phase III | Topotecan Paclitaxel Pegylated liposomal doxorubicin Gemcitabine Olaparib | Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments (SOLO3) | Completed | USA | POL | ITA | ISR | HUN | ESP | CZE | CAN | BRA | BEL | ARG | 2 |
| NCT02316834 | Phase I | Talazoparib | POSITION: A PilOt Study of InducTion PARP InhibitiON in Ovarian Cancer | Completed | USA | 0 |
| NCT02345265 | Phase II | Cediranib + Olaparib | Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer | Active, not recruiting | USA | 0 |
| NCT02354586 | Phase II | Niraparib | A Study of Niraparib in Patients With Ovarian Cancer Who Have Received at Least Three Previous Chemotherapy Regimens | Completed | USA | CAN | 0 |
| NCT02584478 | Phase Ib/II | Anlotinib + Carboplatin + Paclitaxel | Phase 1/2a Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002) | Unknown status | USA | ITA | GBR | ESP | 2 |
| NCT02889900 | Phase II | Cediranib + Olaparib | Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian Cancer (CONCERTO) | Completed | USA | 0 |
| NCT03277209 | Phase I | Plerixafor | To Assess the Safety of Continuous IV Administration of Plerixafor and Assess Impact on the Immune Microenvironment in Patients With Pancreatic, Ovarian and Colorectal Adenocarcinomas | Terminated | USA | GBR | 0 |
| NCT03507452 | Phase I | BAY2287411 | First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin | Completed | USA | SWE | NLD | GBR | FIN | 0 |
| NCT03586661 | Phase I | Copanlisib + Niraparib | Niraparib and Copanlisib in Treating Patients with Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | Active, not recruiting | USA | 0 |
| NCT03608618 | Phase I | MCY-M11 Cyclophosphamide | Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal Mesothelioma | Terminated | USA | 0 |
| NCT03686124 | Phase Ib/II | IMA-203 | ACTengine IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors (ACTengine) | Recruiting | USA | DEU | 0 |
| NCT03733990 | Phase Ib/II | FP-1305 | A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS) | Completed | USA | NLD | GBR | FRA | FIN | ESP | 0 |
| NCT03737643 | Phase III | Bevacizumab + Carboplatin + Paclitaxel Bevacizumab + Carboplatin + Durvalumab + Paclitaxel Bevacizumab + Durvalumab + Olaparib Olaparib Bevacizumab + Durvalumab | Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients. (DUO-O) | Active, not recruiting | USA | TUR | ROU | POL | ITA | HUN | FRA | FIN | ESP | DNK | DEU | CAN | BRA | BGR | BEL | AUT | 4 |
| NCT03839524 | Phase I | TG4050 | A Trial Evaluating TG4050 in Ovarian Carcinoma. | Completed | USA | FRA | 0 |
| NCT03907852 | Phase Ib/II | Gavocabtagene autoleucel + Ipilimumab + Nivolumab Gavocabtagene autoleucel + Nivolumab Gavocabtagene autoleucel Cyclophosphamide + Fludarabine | Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer | Active, not recruiting | USA | CAN | 0 |
| NCT04149145 | Phase I | Niraparib + VX-803 | Trial of M4344 and Niraparib in Patients With Poly (ADP-ribose) Polymerase (PARP) Resistant Recurrent Ovarian Cancer | Withdrawn | 0 | |
| NCT04498117 | Phase III | Carboplatin + Oregovomab + Paclitaxel Carboplatin + Paclitaxel | Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery (FLORA-5) | Active, not recruiting | USA | ITA | HUN | ESP | CZE | CAN | BRA | BEL | ARG | 5 |
| NCT04598321 | Phase I | Talazoparib | BrUOG 390: Neoadjuvant Treatment With Talazoparib | Terminated | USA | 0 |
| NCT04706962 | Phase I | TH1902 | TH1902 in Patients With Advanced Solid Tumors | Active, not recruiting | USA | CAN | 0 |
| NCT04729608 | Phase III | AVB-S6-500 + Paclitaxel Paclitaxel | Study of AVB-S6-500 in Combination With Paclitaxel vs Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer | Terminated | USA | POL | ITA | GBR | FRA | ESP | CZE | CAN | BEL | 2 |
| NCT04884360 | Phase III | Olaparib | D9319C00001- 1L OC Mono Global RCT (MONO-OLA1) | Active, not recruiting | TUR | 9 |
| NCT05032040 | Phase II | XmAb20717 | A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies | Active, not recruiting | USA | 0 |
| NCT05074472 | Phase Ib/II | ZB131 | A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors | Completed | USA | 0 |
| NCT05194072 | Phase I | SGN-B7H4V | A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors | Terminated | USA | GBR | ESP | DEU | CAN | 0 |
| NCT05397093 | Phase I | ITIL-306 | ITIL-306 in Advanced Solid Tumors | Active, not recruiting | USA | 0 |
| NCT05451849 | Phase Ib/II | Cyclophosphamide + Fludarabine TC-510 | A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer | Active, not recruiting | USA | 0 |
| NCT05538624 | Phase Ib/II | AVB-001 | A Study of Intraperitoneally Administered AVB-001 in Patients With Serous Adenocarcinoma of the Ovary | Terminated | USA | 0 |
| NCT05547321 | Phase I | OMTX705 + Pembrolizumab OMTX705 + Tislelizumab OMTX705 | Efficacy and Safety Study of OMTX705, Monotherapy and Anti-PD-1-combined, in Subjects With Advanced Solid Tumors. | Recruiting | USA | ESP | 0 |
| NCT05914116 | Phase Ib/II | DB-1311 + Enzalutamide Abiraterone + DB-1311 DB-1311 | A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors | Recruiting | USA | AUS | 2 |
| NCT06792552 | Phase I | SIM0505 | A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors | Recruiting | USA | 1 |
| NCT06953089 | Phase II | DB-1305 + DB-1311 BNT327 + DB-1311 | DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors | Recruiting | USA | AUS | 2 |
| NCT07148128 | Phase Ib/II | WEF-001 | Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours. | Recruiting | USA | GBR | 0 |